-

Investor Notice: Robbins LLP Informs Investors of the Nano-X Imaging Ltd. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Nano-X Imaging Ltd. (NASDAQ: NNOX) securities between March 31, 2025 and April 17, 2026. Nano-X Imaging Ltd. develops a commercial-grade tomographic imaging device with a digital X-ray source.

Robbins LLP is Investigating Allegations that Nano-X Imaging Ltd. (NNOX) Misled Investors Regarding Its Manufacturing Operations and Financial Condition

Share

For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.

The Allegations: Robbins LLP is Investigating Allegations that Nano-X Imaging Ltd. (NNOX) Misled Investors Regarding Its Manufacturing Operations and Financial Condition

According to the complaint, during the class period, defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects. Specifically, defendants made false and/or misleading statements and/or failed to disclose that: (i) defendants overstated purported efficiency gains achieved in Nano- X’s operations, as well as the purported increased demand for its products; (ii) in reality, Nano-X’s production and manufacturing operations were poorly aligned with demand for the Company’s products; (iii) as a result, Nano-X was experiencing significantly increased operating expenses and cash burn; (iv) the foregoing significantly increased the likelihood that Nano-X would be forced to take disruptive remedial measures with respect to its manufacturing operations, entailing significant restructuring and impairment charges; and (v) as a result, defendants’ public statements were materially false and misleading at all relevant times.

Plaintiff alleges that on April 20, 2026, when Nano-X issued a press release announcing its fourth quarter (“Q4”) 2025 financial results and business updates. Therein, Nano-X reported, inter alia, a Q4 net loss of $33.4 million, mainly due to a $17.5 million charge attributed to impairment of long-lived following a restructuring initiative at its Korean chip manufacturing facility. In explaining the restructuring charge, the press release acknowledged that Nano-X needed to “shift[] to a more efficient outsourced production model that is better aligned with current and anticipated demand.” The same press release also announced that Nano-X’s then-Chief Financial Officer (“CFO”), Defendant Ran Daniel (“Daniel”), would step down as CFO, effective July 31, 2026. On this news, the price of Nano-X’s stock price fell $0.695 per share, or 24.39%, to close at $2.155 per share on April 20, 2026.

What Now: You may be eligible to participate in the class action against Nano-X Imaging Ltd. Shareholders who wish to serve as lead plaintiff for the class should contact Robbins LLP. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002.

To be notified if a class action against Nano-X Imaging Ltd. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NASDAQ:NNOX

Release Versions
$Cashtags

Contacts

Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Social Media Profiles
More News From Robbins LLP

Investor Notice: Robbins LLP Informs Investors of the ADMA Biologics, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired ADMA Biologics, Inc. (NASDAQ: ADMA) securities between August 9, 2024 and March 25, 2026. ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.For more information, submit...

Investor Notice: Robbins LLP Informs Investors of the Erasca, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Erasca, Inc. (NASDAQ: ERAS) securities between January 14, 2025 and April 26, 2026. Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call...

Robbins LLP is Investigating Allegations that the Officers and Directors of Blaize Holdings, Inc. (BZAI) Violated Securities Laws and Breached Fiduciary Duties to Shareholders

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP is investigating Blaize Holdings, Inc. (NASDAQ: BZAI) to determine whether certain Blaize Holdings, Inc. officers and directors violated securities laws and breached fiduciary duties to shareholders. Blaize Holdings, Inc. provides artificial intelligence (AI)-enabled edge computing solutions.In late April 2026, two separate short-seller reports were published within two days of each other, both raising concerns regarding Blaize’...
Back to Newsroom